Navigation Links
Pharmasset Announces Exercise of Underwriters' Overallotment Option

PRINCETON, N.J., Jan. 24, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the underwriters of its recent underwritten public offering have exercised their option to purchase from Pharmasset an additional 495,000 shares of common stock. The net proceeds to Pharmasset after deducting the underwriting discount, from the sale of these additional shares are expected to be approximately $21.9 million. This brings the total expected net proceeds of the offering to Pharmasset, after deducting the underwriting discount and estimated offering expenses, to $123.4 million.  Citi is serving as sole book-running manager for the offering. Morgan Stanley & Co. Incorporated is serving as the co-lead manager, and BofA Merrill Lynch, Leerink Swann LLC and Wedbush PacGrow Life Sciences are serving as co-managers.

Pharmasset granted the option in connection with its previously announced underwritten public offering of 3,300,000 shares of common stock at an offering price of $46.33 per share, of which 1,000,000 shares were offered by the selling stockholders named in the prospectus supplement.  Pharmasset will not receive any proceeds from the sale of shares by the selling stockholders in the offering.  The offering is expected to close on January 26, 2011, subject to customary closing conditions.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Citi at Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, Attention: Prospectus Department, 800-831-9146.

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV).ContactRichard E. T. Smith, Ph.D. VP, Investor Relations and Corporate Office: +1 (609) 613-4181Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts, including, without limitation, statements regarding the net proceeds from the offering and the closing of the offering, are "forward-looking statements" that involve risks, uncertainties and other important factors, including, without limitation, the risk that adverse events could cause a delay of the closing of the offering, the termination of the offering or the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we will be unable to apply the proceeds of the shares being sold by us in the offering as presently intended, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties and important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission.


SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Prices Public Offering of Common Stock
2. Pharmasset Announces Proposed Public Offering of Common Stock
3. Pharmasset Reports Positive Results from its HCV Clinical Programs
4. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset to Present at the JMP Healthcare Conference
8. Pharmasset to Present at the UBS Global Life Sciences Conference
9. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
10. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 - Will ... Medical Education (CME) --> - Will ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) ... products and services, will feature latest diagnostic imaging textbooks and decision ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Research ... of the "Membranes Market - Global Forecast to ... Asia-Pacific , accounting for 37.21% of the ... Asia-Pacific region is projected to ... This growth has been attributed primarily to the fast ...
(Date:11/25/2015)... 2015 --> ... Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, welches ... innehaben, an Enyo Pharma vergeben haben. Im ... gerufenen und von Edelris gemeinsam mit seinen Partnern Inserm ... für HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
(Date:11/24/2015)... ... ... Dr. Kevin Day, local family chiropractor in Warsaw , is hosting a ... During the Indiana winter months, Vitamin D deficiency can lead to Seasonal Affective Disorder ... help provide the tools needed to combat it this year! , “Stress kills us,” ...
Breaking Medicine News(10 mins):